Ki-67 expression and rates of pathologic complete response in T1cN0M0 triple-negative breast cancer: a national cancer database analysis
Treatment sequencing for T1cN0M0 triple-negative breast cancer (TNBC) remains controversial because neoadjuvant chemotherapy (NACT) has not demonstrated improved overall survival (OS) compared to adjuvant chemotherapy (ACT). Using pathologic complete response (pCR) as an early, positive prognostic indicator, this study...